Source:http://linkedlifedata.com/resource/pubmed/id/20653083
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
31
|
pubmed:dateCreated |
2010-7-22
|
pubmed:abstractText |
Significant safety issues have emerged concerning the general use of DRYVAX vaccine. Vaccination with replication-defective recombinant adenovirus (rAd) vaccines may offer a safer and effective alternative to live vaccinia virus (VV) vaccination. Six individual poxvirus glycoproteins: A33R, A34R, A36R, B5R, A27L or L1R that are normally expressed on the surface of infectious vaccinia virus were encoded in rAd vaccines and tested in mice in this study. A single-shot intramuscular injection of rAd encoding A27L protected mice against a lethal intranasal challenge with VV at 4 weeks post-vaccination. By 10 weeks post-vaccination, a significant decrease in post-challenge morbidity was observed that correlated with potent neutralizing antibody responses and the emergence of specific polyfunctional T cell responses. The immunogenicity and protective efficacy of rAd-A27L immunization persisted for at least 35 weeks post-vaccination. This study is the first demonstration that a single-shot subunit vaccine encoding a poxvirus protein confers protection against the mortality and morbidity associated with poxvirus infection.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/A27L protein, Orthopoxvirus,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Smallpox Vaccine,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1873-2518
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
12
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4997-5004
|
pubmed:meshHeading |
pubmed-meshheading:20653083-Adenoviridae,
pubmed-meshheading:20653083-Animals,
pubmed-meshheading:20653083-Antibodies, Viral,
pubmed-meshheading:20653083-Antibody Formation,
pubmed-meshheading:20653083-CD4-Positive T-Lymphocytes,
pubmed-meshheading:20653083-Female,
pubmed-meshheading:20653083-Injections, Intramuscular,
pubmed-meshheading:20653083-Mice,
pubmed-meshheading:20653083-Mice, Inbred BALB C,
pubmed-meshheading:20653083-Neutralization Tests,
pubmed-meshheading:20653083-Respiratory Tract Infections,
pubmed-meshheading:20653083-Smallpox,
pubmed-meshheading:20653083-Smallpox Vaccine,
pubmed-meshheading:20653083-Spleen,
pubmed-meshheading:20653083-Vaccines, Synthetic,
pubmed-meshheading:20653083-Vaccinia virus,
pubmed-meshheading:20653083-Viral Proteins
|
pubmed:year |
2010
|
pubmed:articleTitle |
Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.
|
pubmed:affiliation |
Gene Therapy Program, and Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|